2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining
2009
The Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology
Moran MS, Yang Q, Haffty BG. The Yale University Experience of Early‐Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical‐Pathologic Features, Long‐Term Outcomes, and Molecular Expression of COX‐2, Bcl‐2, and p53 as a Function of Histology. The Breast Journal 2009, 15: 571-578. PMID: 19995377, DOI: 10.1111/j.1524-4741.2009.00833.x.Peer-Reviewed Original ResearchConceptsBreast conservation treatmentInvasive lobular carcinomaInvasive ductal carcinomaEarly-stage invasive lobular carcinomaClinical-pathologic featuresContralateral breast cancerCOX-2Breast relapseILC patientsDuctal carcinomaBreast cancerER/PR/HERBcl-2Cause-specific survivalLong-term outcomesTriple-negative tumorsChemo-preventive strategiesYears of ageImmuno-histochemical analysisExpression of p53Function of histologyDistant relapseInvasive lobularNodal statusContralateral breastClinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy
Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG. Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2009, 76: 679-684. PMID: 19464815, DOI: 10.1016/j.ijrobp.2009.02.050.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalHuman epidermal growth factor receptor 2Cause-specific survivalLower T stageMetastasis-free survivalBreast conservation therapyERCC-1 expressionERCC1 expressionAdjuvant chemotherapyHormonal therapyER positivityOverall survivalT stageConservation therapyProgesterone receptorBreast cancerEstrogen receptorNodal negativityRadiation therapyWorse distant metastasis-free survivalEarly-stage breast cancer patientsLocoregional recurrence-free survivalEarly-stage breast cancerEpidermal growth factor receptor 2Adjuvant hormonal therapy